Multiple neurofibromas as the presenting feature of familial atypical multiple malignant melanoma (FAMMM) syndrome. Issue 6 (23rd April 2013)

• Record Type: Journal Article
• Authors: Vanneste, Rachel; Smith, Erika; Graham, Gail
• Is Part Of: American journal of medical genetics. Volume 161:Issue 6(2013:Jun.)
• Page Start: 1425
• Page End: 1431
• Publication Date: 2013-04-23
• Subjects: Medical genetics -- Periodicals; 616.14205
• DOI: 10.1002/ajmg.a.35884
• Languages: English
• ISSNs: 1552-4825

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="ajmga35884-sec-0001" sec-type="section"> <p>Mutations in the cyclin‐dependent kinase inhibitor‐2A (<italic>CDKN2A</italic>) gene have been associated with a number of malignancies, most notably cutaneous malignant melanoma (CMM). Mutations in this gene have also been associated with pancreatic cancer and breast cancer, as well as astrocytomas and other nervous system tumors (NST). Among NST, rare solitary internal neurofibromas have been reported, but multiple cutaneous neurofibromas have only been described in two families. In the first family, the affected individuals all carried a heterozygous G &gt; C mutation at the splice acceptor site of intron 1 resulting in skipping of <italic>CDKN2A</italic> exon 2, while the affected individuals in the second family had a deletion that encompassed the whole <italic>CDKN2A</italic>/<italic>CDKN2B</italic>/<italic>ANRIL</italic> locus. We now report on a proposita presenting with multiple biopsy‐proven cutaneous neurofibromas and a solitary spinal neurofibroma found to have a deletion of 14 nucleotides in exon 2 of <italic>CDKN2A</italic>, providing further evidence that p14, p16, and/or <italic>ANRIL</italic> are specifically involved in the pathogenesis of neurofibromas as a feature of the familial atypical multiple malignant melanoma spectrum. © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract>